A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated A

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance is a phase 2, interventional study registered as NCT07622550 by Jiangsu Cancer Institute & Hospital, with a registry enrolment figure of 80 participants, started 2026-06-15 and due to reach its primary completion in 2027-12-15. Interventions recorded: Serplulimab+Fruquintinib+XELOX. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Investigator-assessed Progression-Free Survival（PFS）. Colorectal eligibility wording from the registry: "* Diagnosis of advanced unresectable or metastatic colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.